Bobby McMillin

Congress passed a bill last year restricting U.S. pharmaceutical and biotechnology companies from doing business with Chinese firms. Lawmakers are now pushing for additional legislative and regulatory measures to counter China's biopharma rise, while federal health officials aim to ease operations for companies in the U.S. Some legal experts suggest current efforts remain insufficient.